These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

607 related items for PubMed ID: 29631257

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Angiogenesis Inhibitors in NSCLC.
    Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, Piccirillo MC, Daniele G, Perrone F, Rocco G, Morabito A.
    Int J Mol Sci; 2017 Sep 21; 18(10):. PubMed ID: 28934120
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
    Bronte G, Passiglia F, Galvano A, Russo A.
    Expert Opin Biol Ther; 2016 Sep 21; 16(1):1-5. PubMed ID: 26235195
    [Abstract] [Full Text] [Related]

  • 5. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
    Villaruz LC, Socinski MA.
    Curr Oncol Rep; 2015 Jun 21; 17(6):26. PubMed ID: 25947099
    [Abstract] [Full Text] [Related]

  • 6. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
    Epstein Shochet G, Israeli-Shani L, Koslow M, Shitrit D.
    Lung Cancer; 2016 Jun 21; 96():7-14. PubMed ID: 27133742
    [Abstract] [Full Text] [Related]

  • 7. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R, Stewart DJ.
    Clin Cancer Res; 2017 Mar 01; 23(5):1137-1148. PubMed ID: 27940520
    [Abstract] [Full Text] [Related]

  • 8. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
    Losanno T, Rossi A, Maione P, Napolitano A, Gridelli C.
    Expert Opin Biol Ther; 2016 Jun 01; 16(6):747-58. PubMed ID: 26950292
    [Abstract] [Full Text] [Related]

  • 9. Targeting tumor neovasculature in non-small-cell lung cancer.
    Pallis AG, Syrigos KN.
    Crit Rev Oncol Hematol; 2013 May 01; 86(2):130-42. PubMed ID: 23159217
    [Abstract] [Full Text] [Related]

  • 10. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
    Maione P, Sgambato A, Casaluce F, Sacco PC, Santabarbara G, Rossi A, Gridelli C.
    Curr Med Chem; 2017 May 01; 24(1):3-13. PubMed ID: 27855622
    [Abstract] [Full Text] [Related]

  • 11. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K, Duyster J.
    Oncol Res Treat; 2018 May 01; 41(4):166-171. PubMed ID: 29562226
    [Abstract] [Full Text] [Related]

  • 12. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ, Natale RB.
    Semin Oncol; 2005 Dec 01; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [Abstract] [Full Text] [Related]

  • 13. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F, Osswald M, Wick W.
    Oncol Res Treat; 2018 Dec 01; 41(4):181-186. PubMed ID: 29562225
    [Abstract] [Full Text] [Related]

  • 14. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E, Herbst R, Sandler A.
    Clin Adv Hematol Oncol; 2006 Nov 01; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [Abstract] [Full Text] [Related]

  • 15. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
    Di Maio M, Morabito A, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Sandomenico C, Montanino A, Rocco G, Perrone F.
    Curr Pharm Des; 2014 Nov 01; 20(24):3901-13. PubMed ID: 24191956
    [Abstract] [Full Text] [Related]

  • 16. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
    Rossi A, Maione P, Sacco PC, Ambrosio R, Falanga M, Gridelli C.
    Curr Drug Targets; 2010 Jul 01; 11(7):865-8784. PubMed ID: 20412044
    [Abstract] [Full Text] [Related]

  • 17. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.
    Yano S, Matsumori Y, Ikuta K, Ogino H, Doljinsuren T, Sone S.
    Int J Clin Oncol; 2006 Apr 01; 11(2):73-81. PubMed ID: 16622742
    [Abstract] [Full Text] [Related]

  • 18. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
    Greillier L, Tomasini P, Barlesi F.
    Ther Adv Respir Dis; 2016 Oct 01; 10(5):485-91. PubMed ID: 27340254
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
    Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK.
    Proc Natl Acad Sci U S A; 2015 Feb 03; 112(5):1547-52. PubMed ID: 25605928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.